Related Experiment Videos
DMSO protects against adriamycin-induced tissue necrosis
L Lebredo1, R Barrie, E A Woltering
1Department of Surgery, Oregon Health Sciences University, Portland 97201.
The Journal of Surgical Research
|July 1, 1992
Summary
Delivering Adriamycin (Adria) with dimethyl sulfoxide (DMSO) significantly reduced tissue damage and ulcer formation from Adria extravasation. This novel approach lessens the severity of chemotherapy-induced skin injury.
Area of Science:
- Oncology
- Dermatology
- Pharmacology
Background:
- Adriamycin (Adria) extravasation causes severe tissue necrosis due to free radical release.
- Topical dimethyl sulfoxide (DMSO) can mitigate Adria-induced ulcers by scavenging free radicals.
- Early recognition of Adria extravasation is crucial but often challenging.
Purpose of the Study:
- To investigate if co-delivering Adria with low concentrations of DMSO reduces Adria-induced ulcer size and incidence.
- To evaluate the efficacy of DMSO as a vehicle for Adria to prevent extravasation-related tissue damage.
Main Methods:
- 180 male Sprague-Dawley rats were divided into three groups.
- Groups received intradermal injections of Adria diluted in saline, 10% DMSO, or 20% DMSO.
- Ulcer incidence and size were monitored over 4 weeks.
Main Results:
- Delivery of Adria in 10% or 20% DMSO significantly decreased ulcer incidence compared to saline.
- A statistically significant reduction (P<0.001) in ulceration was observed in DMSO-treated groups.
- This indicates DMSO co-administration effectively mitigates Adria-induced skin damage.
Conclusions:
- Co-administration of Adriamycin with 10% or 20% DMSO is a promising strategy to reduce chemotherapy-induced skin ulceration.
- This method offers a potential improvement in managing Adria extravasation.
- Further research may explore optimal DMSO concentrations and clinical applications.